Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
9
×
boston top stories
deals
9
×
national blog main
startups
9
×
biotech
life sciences
national top stories
boston
new york blog main
new york top stories
san francisco blog main
investing
san francisco top stories
clinical trials
fda
glaxosmithkline
ipo
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
cell therapy
crispr
detroit blog main
detroit top stories
eli lilly
fulcrum therapeutics
gene therapy
generic drugs
indiana blog main
indiana top stories
lyra therapeutics
medical device
migraine
national
What
new
9
×
medicines
biotech
therapeutics
address
adds
bio
called
developing
disease
drug
drugs
earlier
million
news
public
roundup
startup
tech
way
absorb
ago
aiming
aims
alliance
allosteric
ambys
approach
approval
areas
bails
based
big
biogen’s
biopharmaceutical
biosciences
bio’s
body
boston
brain
Language
unset
Current search:
new
×
startups
×
" boston blog main "
×
deals
×
@xconomy.com
3 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Boston Tech Watch: Polaris, GE, DataRobot, Facial Recognition Woes
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?